Form D · Biotechnology
Arch Therapeutics, Inc.
Framingham, MA · CIK 0001537561
Offering snapshot reported Jul 19, 2022 · SEC filing
- Reported sold
- $4.23M Offering amount: $4.23M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 6, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 19, 2022 | Initial | $4,230,000 | No comparison | 16 | SEC filing |
| Feb 25, 2021 | Initial | $6,900,000 | No comparison | 9 | SEC filing |
| Jun 15, 2020 | Initial | $550,000 | No comparison | 4 | SEC filing |
| Jun 2, 2016 | Initial | $3,390,601 | No comparison | 18 | SEC filing |
| Mar 17, 2015 | Initial | $750,000 | No comparison | 3 | SEC filing |
| Feb 7, 2014 | Initial | $2,850,000 | No comparison | 9 | SEC filing |
| Jul 8, 2013 | Initial | $7,322,606 | No comparison | 58 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $240K (estimated)
- Finders' fees
- $0
- Form D file number
- 021-452969
Some of the proceeds may be used for general working capital purposes including the payment of salaries and other fees to those listed in Item 3. Additionally, warrants were issued to the placement agent at an exercise price of $0.0503 per share.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Maxim Group LLP | 120708 |
Source: Form D, filed Jul 19, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael S. Abrams | Executive |
| Alan Barber | Executive |
| William Cotter | Executive |
| Richard E. Davis | Executive |
| Avtar Dhillon | Director |
| Punit Dhillon | Director |
| Guy Fish | Director |
| Laurence Hicks | Director |
| Terrence W. Norchi | Director, Executive |
| Arthur Rosenthal | Director |
| James R. Sulat | Director |
| Norchi Terrence | Director, Executive |
| Daniel M. Yrigoyen | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
235 Walnut Street, Suite 6
Framingham, MA, 01702
Framingham, MA, 01702